Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (241-250 of 459) with videos related to

Pageof 46
Sort By:
Current Drug Targets|December 10, 2015
Emerging Immunotargets in Metastatic Renal Cell CarcinomaJohn Kucharczyk, Marc R Matrana, Matteo Santoni, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinomaRoberto Iacovelli, Daniele Santini, Mimma Rizzo, et al.
Clinical Genitourinary Cancer|May 20, 2022
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)Fernando Sabino M Monteiro, Andrey Soares, Vinicius Carrera Souza, et al.
International Journal of Molecular Sciences|June 2, 2021
Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the ClinicAlessia Cimadamore, Liang Cheng, Francesco Massari, et al.
Expert Review of Molecular Diagnostics|December 5, 2019
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkersAntonio Lopez-Beltran, Liang Cheng, Thomas Gevaert, et al.
Future Oncology (London, England)|April 21, 2021
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic reviewAlessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, et al.
Drug Design, Development and Therapy|December 22, 2025
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Journal of Translational Medicine|May 16, 2012
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapyAlessandro Paccapelo, Ivan Lolli, Maria Grazia Fabrini, et al.
Expert Review of Molecular Diagnostics|June 19, 2018
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancerAlessia Cimadamore, Silvia Gasparrini, Matteo Santoni, et al.
Expert Opinion on Emerging Drugs|June 27, 2015
Emerging drugs for the treatment of bone metastasisFrancesco Pantano, Michele Iuliani, Alice Zoccoli, et al.
Pageof 46

Showing results (241-250 of 459) with videos related to

Sort By:
Pageof 46
Current Drug Targets|December 10, 2015
Emerging Immunotargets in Metastatic Renal Cell CarcinomaJohn Kucharczyk, Marc R Matrana, Matteo Santoni, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|August 29, 2015
Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinomaRoberto Iacovelli, Daniele Santini, Mimma Rizzo, et al.
Clinical Genitourinary Cancer|May 20, 2022
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)Fernando Sabino M Monteiro, Andrey Soares, Vinicius Carrera Souza, et al.
International Journal of Molecular Sciences|June 2, 2021
Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the ClinicAlessia Cimadamore, Liang Cheng, Francesco Massari, et al.
Expert Review of Molecular Diagnostics|December 5, 2019
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkersAntonio Lopez-Beltran, Liang Cheng, Thomas Gevaert, et al.
Future Oncology (London, England)|April 21, 2021
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic reviewAlessandro Rizzo, Veronica Mollica, Filippo Gustavo Dall'Olio, et al.
Drug Design, Development and Therapy|December 22, 2025
Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-AnalysisElsa Vitale, Alessandro Rizzo, Lorenza Maistrello, et al.
Journal of Translational Medicine|May 16, 2012
A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapyAlessandro Paccapelo, Ivan Lolli, Maria Grazia Fabrini, et al.
Expert Review of Molecular Diagnostics|June 19, 2018
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancerAlessia Cimadamore, Silvia Gasparrini, Matteo Santoni, et al.
Expert Opinion on Emerging Drugs|June 27, 2015
Emerging drugs for the treatment of bone metastasisFrancesco Pantano, Michele Iuliani, Alice Zoccoli, et al.
Pageof 46